Once-yearly Aclasta Recommended In EU To Treat Male Osteoporosis And Reduce Risk Of New Fractures In Patients After Hip Fracture Male indication important as osteoporosis often neglected in men - ...
Shown to be highly effective in strengthening bones and protecting against fractures in all key sites, including hip and spine[1] Once-yearly dosing provides potential for compliance benefits and long ...
Aclasta reduced the risk of new spine fractures by 52% over six years versus patients who stopped treatment after three years[1] New data from six-year study validate Aclasta safety profile and ...
01 February 2009Single-dose therapy given once a year shown to provide significant bone protection benefits and may improve long-term treatment compliance Amman - Jordan - Aclasta (zoledronic acid 5 ...
LONDON (MarketWatch) -- Swiss drugmaker Novartis said Friday that its Aclasta medicine has been approved in the European Union to treat men and postmenopausal women with osteoporosis caused by ...
ZURICH (Reuters) - Novartis AG's Aclasta was more effective than Procter & Gamble Co's Actonel in increasing bone mass in patients with the bone-thinning disease osteoporosis, a study showed. A ...
Aclasta/Reclast is also approved in the U.S. and EU in men and postmenopausal women with the disease. Novartis’ bisphosphonate infusion, Aclasta®, received approval in the EU for the treatment of men ...
ZURICH, Oct 5 (Reuters) - Swiss drugmaker Novartis AG said on Friday its Aclasta drug had been approved by the European Commission for once-yearly treatment of women with postmenopausal osteoporosis.
EAST HANOVER, N.J., June 5 /PRNewswire/ -- The US Food and Drug Administration (FDA) has broadened the US indication for once-yearly Reclast(R) (zoledronic acid) Injection to include the prevention of ...
MUSCAT -- "Osteoporosis cases in the Middle East are rising, not to be taken by awe, at a galloping speed", says Prof Samir A El Badawy, Professor of Rhematology and Rehabilitation at the Cairo ...
MESSINA, Italy — Although the bisphosphonate zoledronic acid, or zoledronate (Aclasta, Reclast, Novartis), stops bone loss in patients with osteoporosis, it also ups levels of the protein biomarker ...
Approval is reportedly the first to allow dosing every two years. FDA approved Novartis’ Reclast(r) as the first two-yearly treatment for the prevention of postmenopausal osteoporosis. The agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback